2 Top Pot Stocks That Could Disappear by 2025

Both Green Organic Dutchman Holdings Ltd (TSX:GOD) and Cronos Group Inc (TSX:CRON)(NYSE:CRON) are set to grow sales rapidly, but one is a potential buy, while the other may face steep hurdles.

| More on:
Female scientist in a hemp field checking plants and flowers, alternative herbal medicine concept

Image source: Getty Images

After rising several hundred percent in 2018, most cannabis indexes are down 50% or more in 2019. To be sure, underlying growth is still moving higher at a rapid pace. Over the next five years, the cannabis market is expected to grow at more than 20% annually. The issue isn’t demand, but expectations.

As with any other hyper-growth market, pot stocks have undergone the classic hype cycle. Invented by analytics firm Gartner, the hype curve plots an industry or technology on a chart that compares expectations versus reality.

When a new product is first introduced to the mainstream, expectations typically soar, even though full adoption is still years away. When reality doesn’t match up with initial sky-high expectations, investors and analysts often lose hope. This is the best time to buy.

As Warren Buffett often quips, sell when others are greedy, but buy when others are fearful. After a steep and sudden drop in pot stocks, the industry is full of fear, yet it pays to be caution. As Warren Buffett is also known to say: when the tide comes in, you’ll see who’s been swimming naked.

The recent pullback has unearthed some incredible opportunities, but it’s also given us a glimpse into which companies may disappear.

The following two stocks could disappear by 2025, but for very different reasons. One stock is a big opportunity, while the other could go bankrupt.

Lost without a paddle

Last year, Green Organic Dutchman Holdings Ltd (TSX:GOD) was on fire. The stock moved from $4 to $8 per share after it inked a partnership with Aurora Cannabis Inc, which had a $10 billion valuation at the time.

The agreement granted Green Organic critical assistance from Aurora in scaling its grow operations. It also committed Aurora to purchasing 20% of Green Organic’s production.

This September, it all fell apart as Aurora terminated the agreement, putting Green Organic is an incredibly difficult position. Without a cornerstone partner to purchase and promote its cannabis production, the company will enter a fierce, commoditized market.

And while organic pot has fetched a higher price than conventional pot, Green Organic has the potential to flood the market, ruining the entire segment’s excess profits.

Management is putting on a brave face, but Green Organic is stuck upstream without a paddle. Its first two grow facilities reach first production this quarter, and the market isn’t ready for the new supply. Sales are still expected to spike next year, but profits may never come.

Connect the dots

Cronos Group Inc (TSX:CRON)(NYSE:CRON) group, meanwhile, will likely disappear for an exciting reason. In December of 2018, the company struck a transformational deal with tobacco giant Altria Group Inc.

In total, Altria injected $1.8 billion into the company in exchange for an equity stake. Altria will have a 45% stake in Cronos, with options to acquire the entire company down the road.

With Cronos stock moving lower — shares are down 70% since March — Altria may not be able to resist an outright acquisition. Cronos’s market value of $3.6 billion could easily be digested by $100 billion behemoth Altria.

Plus, Altria has faced intense growth headwinds in recent months. What better way to goose long-term growth than to acquire a best-in-class pot company?

It’s too easy to connect the dots here. The lower Cronos stock falls, the more likely a buyout becomes, which could happen well before 2025.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Ryan Vanzo has no position in any stocks mentioned. 

More on Cannabis Stocks

edit Jars of marijuana
Cannabis Stocks

Is Tilray Stock a Buy in the New Bullish Market?

Canadian cannabis producer Tilray has underperformed the broader markets in the last five years due to its weak fundamentals.

Read more »

Bad apple with good apples
Cannabis Stocks

1 TSX Stock I Wouldn’t Touch With a 10-Foot Pole

Down 99% from all-time highs, Aurora Cannabis stock remains a high-risk bet due to its weak fundamentals and risky liquidity…

Read more »

A cannabis plant grows.
Cannabis Stocks

Canopy Growth Stock Has Been on a Roller Coaster: Is it a Good Buy?

In their relatively small lifetime, most cannabis stocks in Canada have seen both extreme highs and massive slumps. But their…

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Canopy Growth Stock Surged 100% Last Month: Is It a Good Buy Now?

Canopy Growth soared more than 160% last month. Can the TSX cannabis stock continue to mover higher in 2024?

Read more »

A cannabis plant grows.
Cannabis Stocks

Canopy Growth Stock Is Rising But I’m Worried About This One Thing

Canopy Growth stock is soaring as the legalization effort makes real progress in both Germany and the United States.

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Why Canopy Growth Stock Could Double in 2024

Canopy Growth (TSX:WEED) stock saw its share more than double in the last two weeks. So, can it do it…

Read more »

Coworkers standing near a wall
Cannabis Stocks

Why Is Everyone Talking About Canopy Growth Stock?

Canopy Growth stock (TSX:WEED) saw shares surge in the last two weeks for a variety of reasons investors can dig…

Read more »

Pot stocks are a riskier investment
Stocks for Beginners

Why Shares of Cannabis Stocks Are Rising This Week

Cannabis stocks received a boost this week as the White House urged the drug enforcement administration to reschedule the drug.

Read more »